Resumen

HERNANDEZ PEREZ, Arianna  y  TIRADO MARTINEZ, Oslay Mijail. Panretinal photocoagulation and intravitreal bevacizumab in the treatment of active proliferative diabetic retinopathy. Rev Cubana Oftalmol [online]. 2014, vol.27, n.1, pp.4-15. ISSN 0864-2176.

Objective: to evaluate the effect of panretinal photocoagulation and intravitreal injection of bevacizumab on neovascularization areas of patients with active proliferative diabetic retinopathy. Methods: experimental study conducted in 80 eyes from 62 patients with proliferative diabetic retinopathy with high risk characteristics. These patients were randomly assigned to panretinal photocoagulation group (group L) or to the panretinal photocoagulation plus intravitreal bevacizumab group (group L + B). The studied variables were age, sex, race, type of diabetes mellitus, illness duration, type of treatment, fluorescein distribution area and retinal/optical disc neovascularization regression area. They were followed-up for 9 months. Results: in the initial evaluation, the average diffusion area was 8,95 mm2 in group L and 10,08 mm2 in group L + B (p = 0,347), which changed to 6,40 mm2 and 3,91 mm2 (p = 0,012) respectively, after one month; 3,15 mm2 and 1,02 mm2 (p = 0,002) three months later, 2,45 mm2 and 0,58 mm2 (p = 0,001) after six months and 2,18 mm2 and 0,46 mm2 (p = 0,001) after nine months, respectively. The analysis of absolute differences of averages showed a significant reduction in the distribution areas of fluorescein that favored the combined therapy. Conclusions: in patients with active proliferative diabetic retinopathy, intravitreal bevacizumab combined with panretinal photocoagulation bring about dramatic regression of neovascularization, which remained stable from the third to the ninth month.

Palabras clave : diabetic retinopathy; pathologic neovascularization; angiogenesis inhibitors; bevacizumab; photocoagulation.

        · resumen en Español     · texto en Español     · Español ( pdf )